BiotechTube

Dantrolene sodium for injectable suspension

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heat Stroke

Conditions

Heat Stroke

Trial Timeline

Sep 1, 2015 → Oct 1, 2015

NCT ID
NCT02513095

About Dantrolene sodium for injectable suspension

Dantrolene sodium for injectable suspension is a phase 2 stage product being developed by Eagle Pharmaceuticals for Heat Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT02513095. Target conditions include Heat Stroke.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02513095Phase 2Completed

Competing Products

13 competing products in Heat Stroke

See all competitors
ProductCompanyStageHype Score
Thermal stress and performance without a pre-cooling protocolPetros PharmaceuticalsPre-clinical
15
AZD7053 + PlaceboAstraZenecaPhase 1
33
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tubeAstraZenecaPhase 1
33
Treatment A (BDA MDI HFO) + Treatment B (BDA MDI HFA)AstraZenecaPhase 1
33
Selumetinib + SirolimusAstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52
imatinib mesylateNovartisPhase 2/3
65
everolimus + bevacizumabNovartisPhase 2
52
IbuprofenPfizerApproved
84
PF-06700841 + ItraconazolePfizerPhase 1
32
Nivolumab + IpilimumabBristol Myers SquibbPhase 1
32
Immune Globulin (Human)GrifolsApproved
82
Ryanodex and Standard of CareEagle PharmaceuticalsPhase 3
69

Other Products from Eagle Pharmaceuticals

Arm 1 Cataract Surgery performed with remimazolam as sedative + Arm 2 Cataract Surgery performed with standard of care sedativeApproved
77
Placebo + Mesalamine + MesalaminePhase 3
69
Ryanodex and Standard of CarePhase 3
69
CAL02 + PlaceboPhase 2
44
Ryanodex (dantrolene sodium) for injectable suspensionPhase 2
44